The team has initiated clinical trials investigating EGFR-, B7H7-, and HER2-CAR-T cells for pediatric CNS tumors and is using this experience to develop multiplexed strategies to overcome challenges such as tumor heterogeneity and confirm feasibility (NCT03638167, NCT04185038, NCT01109095) [50]. Here, ERBB2 is linked to central nervous system neoplasm.